Denovo gains IP from Stanford to develop lead program for new indication

Denovo Biopharma LLC (San Diego, Calif.) received exclusive, worldwide rights to IP from the Stanford University School of Medicine (Stanford, Calif.) that the biotech said will allow it to develop lead program enzastaurin (DB102) for a new indication.

Denovo said research at the university showed the compound modulates a pathway via a "previously unknown drug target which is distinct from DB102's targets for malignancies." The company will evaluate the compound to treat pulmonary arterial hypertension (PAH) "in the near future." The partners declined to provide details...